Summary
The efficacy of tropisetron in the prevention of nausea and vomiting induced by chemotherapy of varying emetogenic potential was evaluated in 545 patients with a variety of malignancies who had either proved refractory to antiemetic treatment during previous chemotherapy courses or who were considered to be at high risk of nausea and vomiting. Tropisetron 5 or 10mg was administered intravenously just before chemotherapy, with the possibility of additional oral or intravenous doses on the day before chemotherapy and on 1 or more subsequent days.
On day 1 of the first course of chemotherapy, a complete response (no nausea and no vomiting) was achieved in 62% of patients and a partial response (1 to 4 vomits and/or episodes of nausea) in 29%. Among the 325 patients who received a second course of chemotherapy, more than 80% of those with a complete response on day 1 of course 1 also had a complete response on day 1 of course 2; 37% and 26%, respectively, of patients with a partial response or failure (1 or more vomits and/or episodes of nausea) on day 1 of course 1 then had a complete response on day 1 of course 2.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aapro MG, Alberts DS. High-dose dexamethasone for cisplatinum-induced vomiting. Cancer Chemotherapy and Pharmacology 7: 11–14, 1981
Bleiberg H, Gerard B, Dalesio O, Crespeigne N, Rozencweig M. Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial. Cancer Chemotherapy and Pharmacology 24: 1093–1095, 1988
Gralla RJ, Clark RA, Kris MG, Tyson LB. Methodology in anti-emetic trials. European Journal of Cancer 27(Suppl. 1): S5–S8, 1991
Gralla RJ, Itri LM, Pisko SE, Squillante AE, Kelsen DP, et al. Antiemetic efficacy of high-dose metoclopramide: randomized trial with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. New England Journal of Medicine 305: 905–909, 1981
Kris MG, Gralla RJ, Clark RA, Tyson LB, Flore JJ, et al. Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: improved subjective effectiveness over the combination of diphenhydramine plus dexamethasone. Cancer Treatment Reports 69: 1257–1262, 1985
Leibundgut U, Lancranjan I. First results with ICS 205-930 (5-HT3 receptor antagonist) in prevention of chemotherapy-induced emesis. Lancet 1: 1198, 1987
Marty M, Pouillart P, Scholl S, Droz JP, Azab M, et al. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. New England Journal of Medicine 322: 816–820, 1990
Roila F, Tonato M, Basurto C, Bella M, Passalcqua R, et al. Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. Journal of Clinical Oncology 5: 141–149, 1987
Seinen H, Zonnenberg BA, Tjia P, Neijt JP. The effect of three dose levels of ICS 205-930 (a selective 5-HT3 antagonist) on cisplatin-induced nausea and vomiting. European Journal of Cancer and Clinical Oncology 25: 1333–1335, 1989
Tyson LB, Gralla RJ, Kris MG, Clark RA. Phase I antiemetic study of the serotonin antagonist ICS 205-930. Proceedings of ASCO Vol. 8: 331, 1989
Author information
Authors and Affiliations
Additional information
† For a list of other investigators see p. 31
Rights and permissions
About this article
Cite this article
Bleiberg, H., Van Belle, S., Paridaens, R. et al. Compassionate Use of a 5-HT3-Receptor Antagonist, Tropisetron, in Patients Refractory to Standard Antiemetic Treatment. Drugs 43 (Suppl 3), 27–32 (1992). https://doi.org/10.2165/00003495-199200433-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199200433-00007